Kisqali® Adds One More Year Of Survival Benefit For Broadest Set Of Patients, Including Those With Aggressive HR+/HER2- Advanced Breast Cancer September 13, 2022
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant mNSCLC September 13, 2022